🚀 VC round data is live in beta, check it out!
Sinocelltech Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sinocelltech Group and similar public comparables like Arcutis Biotherapeutics, Arcus Biosciences, Vera Therapeutics, Grand Pharmaceutical and more.
Sinocelltech Group Overview
About Sinocelltech Group
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Founded
2007
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$3B
Sinocelltech Group Financials
Sinocelltech Group reported last fiscal year revenue of $368M and EBITDA of $55M.
In the same fiscal year, Sinocelltech Group generated $353M in gross profit, $55M in EBITDA, and $16M in net income.
Revenue (LTM)
Sinocelltech Group P&L
In the most recent fiscal year, Sinocelltech Group reported revenue of $368M and EBITDA of $55M.
Sinocelltech Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $368M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $353M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 96% | XXX | XXX | XXX |
| EBITDA | — | XXX | $55M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 27% | XXX | XXX | XXX |
| Net Profit | — | XXX | $16M | XXX | XXX | XXX |
| Net Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $242M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sinocelltech Group Stock Performance
Sinocelltech Group has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Sinocelltech Group's stock price is $6.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSinocelltech Group Valuation Multiples
Sinocelltech Group trades at 9.4x EV/Revenue multiple, and 63.1x EV/EBITDA.
EV / Revenue (LTM)
Sinocelltech Group Financial Valuation Multiples
As of April 19, 2026, Sinocelltech Group has market cap of $3B and EV of $3B.
Equity research analysts estimate Sinocelltech Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sinocelltech Group has a P/E ratio of 185.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 63.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 34.6x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 9.8x | XXX | XXX | XXX |
| P/E | — | XXX | 185.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (93.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sinocelltech Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sinocelltech Group Margins & Growth Rates
Sinocelltech Group's revenue in the last fiscal year grew by 33%.
Sinocelltech Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 33% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (319%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sinocelltech Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcutis Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcus Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Vera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Grand Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Apeloa Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sinocelltech Group M&A Activity
Sinocelltech Group acquired XXX companies to date.
Last acquisition by Sinocelltech Group was on XXXXXXXX, XXXXX. Sinocelltech Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sinocelltech Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSinocelltech Group Investment Activity
Sinocelltech Group invested in XXX companies to date.
Sinocelltech Group made its latest investment on XXXXXXXX, XXXXX. Sinocelltech Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sinocelltech Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sinocelltech Group
| When was Sinocelltech Group founded? | Sinocelltech Group was founded in 2007. |
| Where is Sinocelltech Group headquartered? | Sinocelltech Group is headquartered in China. |
| Is Sinocelltech Group publicly listed? | Yes, Sinocelltech Group is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Sinocelltech Group? | Sinocelltech Group trades under 688520 ticker. |
| When did Sinocelltech Group go public? | Sinocelltech Group went public in 2020. |
| Who are competitors of Sinocelltech Group? | Sinocelltech Group main competitors are Arcutis Biotherapeutics, Arcus Biosciences, Vera Therapeutics, Grand Pharmaceutical. |
| What is the current market cap of Sinocelltech Group? | Sinocelltech Group's current market cap is $3B. |
| What is the current revenue of Sinocelltech Group? | Sinocelltech Group's last fiscal year revenue is $368M. |
| What is the current EV/Revenue multiple of Sinocelltech Group? | Current revenue multiple of Sinocelltech Group is 9.4x. |
| Is Sinocelltech Group profitable? | No, Sinocelltech Group is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.